Design Therapeutics, Inc. ( DSGN ) NASDAQ Global Select

Cena: 4.16 ( -2.46% )

Aktualizacja 07-24 19:44
NASDAQ Global Select
Branża: Biotechnology

Notowania:


Opis firmy:

Design Therapeutics, Inc. Firma biofarmaceutyczna przedkliniczna, angażuje się w opracowywanie terapii w leczeniu chorób genetycznych spowodowanych przez powtarzanie nukleotydów. Portfolio produktów firmy obejmuje Friedreicha ataksji, monogeniczną, autosomalną recesywną, postępującą wielosystemową chorobę, która wpływa na układy narządów zależne od funkcji mitochondriów, ostatecznie prowadzącą do dysfunkcji neurologicznej, sercowej i metabolicznej; oraz dystrofii miotoniczne typu 1 (DM1), dominująco zołaczona, monogeniczna postępująca choroba nerwowo-mięśniowa wpływająca na mięśnie szkieletowe, serce, mózg i inne narządy. Opracowuje również portfel kandydujący produkt genetac do leczenia innych monogennych chorób monogennych napędzanych ekspansją nukleotydów, takich jak kruche zespół X, atraki mięśniowe spinokerebellarne, atrofii mięśniowo-amiotroficzne. Design Therapeutics, Inc. został zarejestrowany w 2017 roku i ma siedzibę w Carlsbad w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 54
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 58.1359
Ilość akcji: Brak danych
Debiut giełdowy: 2021-03-29
WWW: https://www.designtx.com
CEO: Mr. Pratik Shah Ph.D.
Adres: 6005 Hidden Valley Road
Siedziba: 92011 Carlsbad
ISIN: US25056L1035
Wskaźniki finansowe
Kapitalizacja (USD) 236 441 636
Aktywa: 261 629 000
Cena: 4.16
Wskaźnik Altman Z-Score: 23.0
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -4.2
Ilość akcji w obrocie: 58%
Średni wolumen: 100 768
Ilość akcji 56 768 700
Wskaźniki finansowe
Przychody TTM 838 000
Zobowiązania: 9 176 000
Przedział 52 tyg.: 2.6 - 7.77
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -1.0
P/E branży: 26.1
Beta: 1.833
Raport okresowy: 2025-08-04
WWW: https://www.designtx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Pratik Shah Ph.D. Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson 704 100 1970
Dr. Sean Jeffries Ph.D. Chief Operating Officer 554 013 1980
Mr. Mustapha Parekh General Counsel 0 0
Ms. Dawn Giangiulio Controller 0 0
Ms. Julie D. Burgess CPA Chief Accounting Officer 0 0
Dr. Jae B. Kim FACC, M.D. Chief Medical Officer 0 1970
Dr. Aseem Z. Ansari Ph.D. Co-Founder & Scientific Advisor 0 0
Lista ETF z ekspozycją na akcje Design Therapeutics, Inc.
Symbol ETF Ilość akcji Wartość
IWM 829 036 2 934 786
IWN 286 815 1 015 325
IBB 198 679 703 323
VTWO 156 448 583 551
SCHA 136 910 516 150
FESM 79 254 291 654
IWC 74 803 264 801
ONEQ 57 533 216 899
DFAT 48 890 184 315
AVSC 41 456 156 289
BTEC.L 32 808 116 138
2B70.DE 32 808 116 138
BTEE.L 32 808 116 138
BTEK.L 32 808 116 138
SCHB 26 443 99 690
VTWV 21 471 80 086
RSSL 17 867 74 505
DFAS 14 951 56 365
IWV 9 408 33 304
XSU.TO 5 519 26 655
DFAU 3 639 13 719
OMFS 3 308 12 471
UWM 3 199 12 060
URTY 2 656 10 013
IBBQ 2 337 8 810
VTHR 2 331 8 694
DFUS 2 323 8 757
BIB 2 091 7 883
HDG 40 150
DCOR 16 60
Wiadomości dla Design Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. globenewswire.com 2025-05-13 12:00:00 Czytaj oryginał (ang.)
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy  (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025. globenewswire.com 2025-05-07 20:01:00 Czytaj oryginał (ang.)
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 globenewswire.com 2025-05-01 12:00:00 Czytaj oryginał (ang.)
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients. globenewswire.com 2025-04-21 20:01:00 Czytaj oryginał (ang.)
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. globenewswire.com 2025-04-17 12:00:00 Czytaj oryginał (ang.)
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-03-12 15:01:03 Czytaj oryginał (ang.)
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 globenewswire.com 2025-03-10 09:07:00 Czytaj oryginał (ang.)
Design Therapeutics to Participate in Leerink's Global Healthcare Conference CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. globenewswire.com 2025-03-03 10:00:00 Czytaj oryginał (ang.)
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-11-13 10:00:00 Czytaj oryginał (ang.)
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced its third quarter 2024 financial results and reviewed anticipated upcoming program milestones for its portfolio of GeneTAC™ candidates. globenewswire.com 2024-11-07 18:01:00 Czytaj oryginał (ang.)
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-08-21 14:55:55 Czytaj oryginał (ang.)
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials globenewswire.com 2024-08-05 12:00:00 Czytaj oryginał (ang.)
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. investorplace.com 2024-05-23 00:50:47 Czytaj oryginał (ang.)
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones. globenewswire.com 2024-05-08 20:05:00 Czytaj oryginał (ang.)
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. globenewswire.com 2024-05-07 10:30:00 Czytaj oryginał (ang.)
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript seekingalpha.com 2024-03-19 22:44:02 Czytaj oryginał (ang.)
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 globenewswire.com 2024-03-19 18:01:00 Czytaj oryginał (ang.)
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. globenewswire.com 2024-03-12 08:30:00 Czytaj oryginał (ang.)
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2023-12-18 15:32:15 Czytaj oryginał (ang.)
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results. globenewswire.com 2023-11-13 18:05:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. prnewswire.com 2023-10-09 23:02:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). prnewswire.com 2023-09-29 22:54:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). prnewswire.com 2023-09-21 23:56:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). prnewswire.com 2023-09-13 23:20:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). prnewswire.com 2023-09-05 23:14:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. prnewswire.com 2023-08-28 22:11:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. prnewswire.com 2023-08-19 00:15:00 Czytaj oryginał (ang.)
Why Shares of Design Therapeutics Are Plummeting on Tuesday Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026. fool.com 2023-08-15 19:02:00 Czytaj oryginał (ang.)